KR920701451A - 인체혈청알부민의 n-말단 단편을 함유하는 융합 단백질 - Google Patents

인체혈청알부민의 n-말단 단편을 함유하는 융합 단백질

Info

Publication number
KR920701451A
KR920701451A KR1019910701334A KR910701334A KR920701451A KR 920701451 A KR920701451 A KR 920701451A KR 1019910701334 A KR1019910701334 A KR 1019910701334A KR 910701334 A KR910701334 A KR 910701334A KR 920701451 A KR920701451 A KR 920701451A
Authority
KR
South Korea
Prior art keywords
variant
terminus
parts
fusion polypeptide
hsa
Prior art date
Application number
KR1019910701334A
Other languages
English (en)
Other versions
KR100227167B1 (ko
Inventor
제임스 발란스 데이비드
Original Assignee
데이비드 헤스
델타 바이오테크노로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 헤스, 델타 바이오테크노로지 리미티드 filed Critical 데이비드 헤스
Publication of KR920701451A publication Critical patent/KR920701451A/ko
Application granted granted Critical
Publication of KR100227167B1 publication Critical patent/KR100227167B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

인체혈청알부민의 N-말단 단편을 함유하는 융합 단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도(2매)는, 별도의 HSA(1-n)의 C-말단을 가진(네모안에), 천연 HSA의 가장 대표적인 것으로 일반적으로 생각되는 아미노산 배열을 나타낸다. 제2도(2매)는, 성숙 HSA를 코드화하는 DNA 배열을 나타내는데, 링커3에 내포된 배열에는 밑줄을 쳤다. 제3도는 mHOB16의 구조를 개략적으로 예시한다.

Claims (7)

  1. N-말단부의 최소한 일부로서, HSA의 N-말단부 또는 그 변이체와, C-말단부와 최소한 일부로서는, 상기 HSA의 N-말단부가 1-n부(여기서 n은 369~419)또는 그 변이체일 때 폴리펩티드가, (a)인체 피브로넥틴(fibronectin)의 585~1578부 또는 그 변이체, (b) CD4의 1~368부 또는 그 변이체, (c)혈소판 유래 성장인자 또는 그 변이체 1~261부 또는 그 변이체, (d)형질전환 성장인자 β또는 그 변이체, (f)성숙 인체 플라즈마 피브로넥틴의 278~578부 또는 그 변이체, (g)성숙 인체 본 월레브란드 인자(Von Willebrand's Factor)의 1-272부 또는 그 변이체 또는 (h)알파-1-아티트립신 또는 그 변이체인 것을 제외한, 기타의 폴리펩티드를 포함하는 융합 폴리펩티드.
  2. 제1항에 있어서, HSA의 N-말단부에 대응하는 부분을 지나서 뻗는 하나 이상의 N-말단 아미노산을 추가로 포함하는 융합폴리펩티드.
  3. 제1항 또는 2항에 있어서, 상기 N-말단 또는 C-말단부의 접합점에 분열 가능한 영역이 있는 융합 폴리펩티드.
  4. 제1항 내지 제3항의 어느 한 항에 있어서, C-말단부가 인체 플라스마 피브로넥틴의 585-1578부 또는 그 변이체인 융합.
  5. 전항중의 어느 한 항에 따른 융합 폴리펩티드를 발현하도록 배열된, 뉴클레오티드 배열을 갖는 형질전환 또는 형질이입된 숙주.
  6. 제5항에 의한 숙주를 배양한 후 유용한 형태로 융합 폴리펩티드를 분리함으로써 융합 폴리펩티드를 제조하는 방법.
  7. 치료용 목적의, 제1항 내지 제4항중의 어느 한 항에 의한 융합 폴리펩티드.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910701334A 1989-04-29 1991-10-14 인체혈청알부민의 n-말단 단편을 함유하는 융합단백질 KR100227167B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB89099162 1989-04-29
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
GB8909916.2 1989-04-29

Publications (2)

Publication Number Publication Date
KR920701451A true KR920701451A (ko) 1992-08-11
KR100227167B1 KR100227167B1 (ko) 1999-10-15

Family

ID=10656000

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701334A KR100227167B1 (ko) 1989-04-29 1991-10-14 인체혈청알부민의 n-말단 단편을 함유하는 융합단백질

Country Status (12)

Country Link
EP (1) EP0470165A1 (ko)
JP (1) JP2781459B2 (ko)
KR (1) KR100227167B1 (ko)
AU (1) AU630450B2 (ko)
CA (1) CA2015687C (ko)
FI (1) FI104255B1 (ko)
GB (2) GB8909916D0 (ko)
HU (1) HUT61049A (ko)
IE (1) IE67651B1 (ko)
IL (1) IL94243A (ko)
WO (1) WO1990013653A1 (ko)
ZA (1) ZA903237B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
AR008077A1 (es) * 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
KR20010034305A (ko) 1998-01-23 2001-04-25 한센 핀 베네드 효모에서 원하는 폴리펩티드를 만드는 방법
US6548653B1 (en) 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
ES2484966T3 (es) * 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
CN101633907B (zh) 2001-08-15 2012-09-05 宝生物工程株式会社 抗原特异性细胞毒性t细胞的扩大培养方法
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
ATE491021T1 (de) 2002-03-25 2010-12-15 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten
CN1839202B (zh) * 2003-08-22 2012-07-18 宝生物工程株式会社 细胞毒性淋巴细胞的制备方法
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
WO2006067511A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
DK2049560T3 (da) 2006-07-13 2013-07-29 Novozymes Biopharma Dk As Fremgangsmåde til fremstilling af partikler af proteinholdigt materiale
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
EP3628327A1 (en) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
CA3043179A1 (en) * 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides

Also Published As

Publication number Publication date
GB9119043D0 (en) 1991-12-04
CA2015687C (en) 2000-08-29
JPH04506598A (ja) 1992-11-19
GB8909916D0 (en) 1989-06-14
IL94243A (en) 1995-10-31
HU904413D0 (en) 1992-01-28
CA2015687A1 (en) 1990-10-29
GB2246783B (en) 1992-10-14
WO1990013653A1 (en) 1990-11-15
IE67651B1 (en) 1996-04-17
FI104255B (fi) 1999-12-15
FI915073A0 (fi) 1991-10-28
EP0470165A1 (en) 1992-02-12
KR100227167B1 (ko) 1999-10-15
AU5564690A (en) 1990-11-29
IE901554L (en) 1990-10-29
JP2781459B2 (ja) 1998-07-30
FI104255B1 (fi) 1999-12-15
GB2246783A (en) 1992-02-12
IL94243A0 (en) 1991-01-31
AU630450B2 (en) 1992-10-29
ZA903237B (en) 1991-03-27
HUT61049A (en) 1992-11-30

Similar Documents

Publication Publication Date Title
KR920701451A (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합 단백질
KR890006668A (ko) 폴리펩티드
MD2311G2 (ro) Polipeptide de obezitate, fragment imunogen, analog, analog uman şi analog uman redus, moleculă de acid nucleic izolată, moleculă de ADN, moleculă de acid nucleic marcată detectabil, vectori conţinând molecula ADN, anticorp monoclonal, anticorp policlonal şi compoziţie farmaceutică pentru reducerea greutăţii corporale a animalelor
KR960701899A (ko) 인자 viii:c활성을 갖는 단백질 복합체 및 그의 제조
Ishibashi et al. Assignment of disulfide bond location in prothoracicotropic hormone of the silkworm, Bombyx mori: a homodimeric peptide
KR880700858A (ko) 재조합된 인간의 내피성 세포의 생장인자
ATE272109T1 (de) Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
DE69132902D1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
Keller et al. Abalone (Haliotis tuberculata) hemocyanin type 1 (HtH1) Organization of the≈ 400 kDa subunit, and amino acid sequence of its functional units f, g and h
EP0546110A4 (en) New insulin-like growth factor binding protein igfbp-5
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
CA2202639A1 (fr) Proteines recombinantes de l'hemagglutinine filamenteuse de bordetella, notamment bordetella pertussis, procede pour leur production et leurs applications a la production de proteines etrangeres ou de principes actifs vaccinants
KR900014428A (ko) 신규폴리펩타이드 및 그 제조방법
DE69132813T2 (de) Genetisches igfbp-5 rodierendes material
KR870010193A (ko) 인체 췌장 엘라스타제 i
KR940021579A (ko) 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
NO20020012D0 (no) Reseptor for neurotrofisk faktor
EP0232107A3 (en) Human lymphotoxin polypeptide derivative
KR910016923A (ko) 트롬빈 결합성 물질의 제조법
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
CA2429138A1 (en) Sol-fusin: use of gp64-6his to catalyze membrane fusion
Koteliansky et al. The effect of non-muscle tropomyosin on the interaction of filamin with F-actin
KR900008040A (ko) 스트렙토마이세테스 내에서 인슐린 전구체를 제조하는 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

S901 Examination by remand of revocation
E902 Notification of reason for refusal
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110620

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee